Amgen shutters Vectibix trial on safety questions

Shares of biotech giant Amgen took a beating after researchers announced late Thursday that they were pulling the plug on a trial adding Vectibix to chemotherapy and Avastin for metastatic colorectal cancer. Amgen shares dropped 4.3 percent in pre-market trading when an interim analysis of the data showed that the control arm had a statistically significant advantage in progression-free survival.

"We had hoped that adding Vectibix to the current U.S. standard-of-care for patients newly diagnosed with (metastatic colorectal cancer) would improve outcomes without excessive added toxicity," said Roger Perlmutter, Amgen's executive vice president of research and development, in a statement. "Unfortunately, it appears that adding Vectibix to Avastin, when used in combination with oxaliplatin- or irinotecan-based chemotherapy, increased toxicity without improving efficacy," he added.

The news proved a tonic for ImClone, which makes Erbitux. Its shared jumped 19 percent. Merck KGaA, which markets Erbitux outside of the U.S. and Canada, also saw its shares climb.

- see Amgen's release for more
- here's the report from Dow Jones on Vectibix

ALSO: Amgen CEO Kevin Sharer made $24 million last year and Roger Perlmutter, head of R&D, took home $10 million. Report

Related Articles:
Amgen launches price war on Vectibix OK. Report
Avastin encounters rare failure for pancreatic cancer. Report
ImClone touts increased survival rate in Erbitux cancer trial. Report

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.